European Archives - Page 565 of 1108 - European Medical Journal

Preparing for the next pandemic

The pharmaceutical industry could have been better prepared for the COVID-19 pandemic. What did they learn that will help them respond better in the future?

A debate on digital transformation

In this roundtable, three thought leaders detail the barriers in the way of digital transformation and outline their vision for the future.

What lessons can pharma learn from Silicon Valley?

How can pharma transform its approach to patients by introducing digital platforms and virtual care into their spaces?

Finding Humanity with AI

How can AI help MA retain their human touch as the industry reimagines the field and creates a best-in-class function?

A Novel Algorithm to Treat Chronic Coronary Total Occlusions

In this webinar, Pierfrancesco Agostoni, Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium presents a simpler and more efficient approach for percutaneous coronary intervention (PCI) of chronic coronary total occlusion (CTO), termed the Minimalistic Hybrid Approach (MHA). Agostoni discusses how MHA helps to downsize the set-up procedure but also helps to achieve minimal invasiveness by improving elements such as the access site, dual injection, and introducer size, while at the same time maintaining the efficiency and success rate of the classic algorithm approach.

EMJ Hematology 9 [Supplement 3] 2021 Feature Image

FLT3 Mutations in Patients with Acute Myeloid Leukaemia: The Importance of Identification and Monitoring for Prognostic Determination and the Selection of Optimal Treatment Strategies

Mutations in FLT3 are the most common genetic alteration in AML. Patients with a FLT3 internal tandem duplication (ITD) mutation subtype have poor prognosis, especially when there is a high allelic burden.

EMJ Hematology 9 [Supplement 3] 2021 Feature Image

EMJ Hematology 9 [Supplement 3] 2021

In this supplement to EMJ Hematology, two leading haematologists, Prof Adriano Venditti and Prof Lars Bullinger, discussed the management…

EMJ Podcast: FLT3 Mutations in Patients with AML

In this episode, we discuss the treatment of patients who have acute myeloid leukemia (AML) as well as FMS-like tyrosine kinase 3 gene (FLT3) mutations.

Dynamic AFP-R and Patient Outcomes After Liver Transplant for Hepatocellular Carcinoma

Karim Halazun, Associate Professor of Surgery, Weill Cornell Medicine, New York City, New York, USA, and colleagues explored whether the dynamic α-fetoprotein response (AFP-R) could improve pre-operative prediction of patient outcomes.

A Novel Immunotherapeutic Approach to Combat Hepatitis B

Globally, chronic hepatitis B virus (HBV) infection is associated with substantial liver-related morbidity and mortality, causing an estimated 800,000 deaths from complications such as cirrhosis and hepatocellular carcinoma. Now, a new immunotherapy strategy identified by researchers at University College London (UCL), UK, could transform the treatment landscape of HBV.